Joseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $55.39, for a total value of $166,170.00. Following the transaction, the director now directly owns 7,127 shares in the company, valued at approximately $394,764.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down $1.04 during trading on Tuesday, hitting $54.84. The company had a trading volume of 527,200 shares, compared to its average volume of 1,507,986. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. Ionis Pharmaceuticals, Inc. has a 12-month low of $37.26 and a 12-month high of $65.51. The stock has a market capitalization of $6,610.00, a P/E ratio of 372.53 and a beta of 2.89.

ILLEGAL ACTIVITY NOTICE: “Joseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/15/joseph-klein-iii-sells-3000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

Several institutional investors have recently bought and sold shares of the stock. Hanseatic Management Services Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.2% in the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Ionis Pharmaceuticals by 0.4% in the second quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock valued at $492,000 after buying an additional 43 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its stake in shares of Ionis Pharmaceuticals by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock valued at $1,241,000 after buying an additional 65 shares in the last quarter. World Asset Management Inc boosted its stake in shares of Ionis Pharmaceuticals by 3.4% in the second quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock valued at $286,000 after buying an additional 187 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares in the last quarter. Hedge funds and other institutional investors own 88.98% of the company’s stock.

IONS has been the topic of several research analyst reports. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research report on Monday, July 31st. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Sunday, September 17th. Barclays PLC initiated coverage on Ionis Pharmaceuticals in a research report on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $50.31.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply